Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 250Carcinoma, Renal Cell 89Urinary Bladder Neoplasms 67Breast Neoplasms 41Carcinoma, Transitional Cell 37Colorectal Neoplasms 33Ovarian Neoplasms 32Melanoma 31Carcinoma, Non-Small-Cell Lung 31Kidney Neoplasms 30Neoplasms 28Neoplasm Metastasis 26Sarcoma 25Uterine Cervical Neoplasms 20Lung Neoplasms 20Endometrial Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Wilms Tumor 17Adenocarcinoma 17Stomach Neoplasms 16Pancreatic Neoplasms 16Carcinoma, Hepatocellular 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12Head and Neck Neoplasms 12

Interventions

enzalutamide 2apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × 30 days × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡